Effectiveness of Empiric Carbapenem Versus Non-carbapenem Therapy for Extended-spectrum β-lactamase Producing Enterobacterales Infections in Non-intensive Care Unit Patients: a Real-world Investigation in a Hospital with High-prevalence Of...

Overview

Journal Antimicrob Steward Healthc Epidemiol

Publisher Cambridge University Press

Specialty Infectious Diseases

Date 2024 Jun 5

PMID 38836043

Authors

Amy Y Kang

Mary Elkomos

Danny Pham

Michelle Guerrero

Deborah Kupferwasser

Loren G Miller

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate whether empiric carbapenem therapy, compared to empiric non-carbapenem therapy, was associated with improved clinical outcomes among hospitalized, non-intensive care unit (ICU) patients with extended-spectrum β-lactamase (ESBL)-producing Enterobacterales infections.

Methods: We performed a retrospective cohort study of adult, non-ICU patients admitted with ESBL-producing Enterobacterales infections. Primary outcome was time to clinical stability from the first empiric antibiotic dose. Secondary outcomes were early clinical response and 30-day all-cause hospital readmission. We used multivariate regression methods to examine time to clinical stability.

Results: Of the 142 patients, 59 (42%) received empiric carbapenems and 83 (58%) received empiric non-carbapenems, most commonly ceftriaxone (49/83, 59%). Median age was 59 years. The most common infection source was urinary (71%). The carbapenem group had a higher proportion of patients who received antibiotics within 6 months of admission (55% vs 28%, < .01) and history of ESBL (57% vs 17%, < .01). There were no significant differences in hours until clinical stability between the carbapenem and non-carbapenem groups (22 (IQR: 0, 85) vs 19 (IQR: 0, 69), = .54). Early clinical response (88% vs 90%, = .79) and 30-day all-cause hospital readmission (17% vs 8%, = .13) were similar between groups.

Conclusion: Among hospitalized non-ICU patients with ESBL-producing Enterobacterales infection, we found no difference in time to clinical stability after the first empiric antibiotic dose between those receiving carbapenems and those who did not. Our data suggest that empiric carbapenem use may not be an important driver of clinical response in patients with less severe ESBL-producing Enterobacterales infection.

References

Teshome B, Vouri S, Hampton N, Kollef M, Micek S . Duration of Exposure to Antipseudomonal β-Lactam Antibiotics in the Critically Ill and Development of New Resistance. Pharmacotherapy. 2018; 39(3):261-270. PMC: 6507412. DOI: 10.1002/phar.2201. View

Zhu C, Wang D, Zi H, Huang Q, Gu J, Li L . Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Mil Med Res. 2021; 8(1):64. PMC: 8656041. DOI: 10.1186/s40779-021-00359-8. View

Ramirez J, Tzanis E, Curran M, Noble R, Chitra S, Manley A . Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice. Clin Infect Dis. 2019; 69(Suppl 1):S33-S39. PMC: 6669292. DOI: 10.1093/cid/ciz397. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Raphael E, Glymour M, Chambers H . Trends in prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolated from patients with community- and healthcare-associated bacteriuria: results from 2014 to 2020 in an urban safety-net healthcare system. Antimicrob Resist Infect Control. 2021; 10(1):118. PMC: 8359060. DOI: 10.1186/s13756-021-00983-y. View

Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith C, French C . Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021; 49(11):e1063-e1143. DOI: 10.1097/CCM.0000000000005337. View

Toledo D, Soldevila N, Torner N, Perez-Lozano M, Espejo E, Navarro G . Factors associated with 30-day readmission after hospitalisation for community-acquired pneumonia in older patients: a cross-sectional study in seven Spanish regions. BMJ Open. 2018; 8(3):e020243. PMC: 5884368. DOI: 10.1136/bmjopen-2017-020243. View

Meije Y, Pigrau C, Fernandez-Hidalgo N, Clemente M, Ortega L, Sanz X . Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study. Int J Antimicrob Agents. 2019; 54(2):189-196. DOI: 10.1016/j.ijantimicag.2019.05.004. View

Kumar A, Roberts D, Wood K, Light B, Parrillo J, Sharma S . Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006; 34(6):1589-96. DOI: 10.1097/01.CCM.0000217961.75225.E9. View

10.

Rhodes A, Evans L, Alhazzani W, Levy M, Antonelli M, Ferrer R . Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017; 43(3):304-377. DOI: 10.1007/s00134-017-4683-6. View

11.

Tamma P, Rodriguez-Bano J . The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections. Clin Infect Dis. 2017; 64(7):972-980. PMC: 5848369. DOI: 10.1093/cid/cix034. View

12.

Raya-Cruz M, Payeras-Cifre A, Ventayol-Aguilo L, Diaz-Antolin P . Factors associated with readmission and mortality in adult patients with skin and soft tissue infections. Int J Dermatol. 2019; 58(8):916-924. DOI: 10.1111/ijd.14390. View

13.

Nordmann P, Poirel L . Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. Clin Infect Dis. 2019; 69(Suppl 7):S521-S528. PMC: 6853758. DOI: 10.1093/cid/ciz824. View

14.

Muhammed M, Flokas M, Detsis M, Alevizakos M, Mylonakis E . Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing : A Systematic Review and Meta-Analysis. Open Forum Infect Dis. 2017; 4(2):ofx099. PMC: 5499850. DOI: 10.1093/ofid/ofx099. View

15.

Chastain D, White B, Cretella D, Bland C . Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review. Ann Pharmacother. 2017; 52(5):484-492. DOI: 10.1177/1060028017748943. View

16.

Anderson D, Albrecht B, Ashley Jones K, Jacob J, Sexton M, Wiley Z . Efficacy of Noncarbapenem β-Lactams Compared to Carbapenems for Extended-Spectrum β-Lactamase-Producing Enterobacterales Urinary Tract Infections. Open Forum Infect Dis. 2022; 9(3):ofac034. PMC: 8843075. DOI: 10.1093/ofid/ofac034. View

17.

Vardakas K, Tansarli G, Rafailidis P, Falagas M . Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012; 67(12):2793-803. DOI: 10.1093/jac/dks301. View

18.

Alexander E, Goldberg L, Das A, Moran G, Sandrock C, Gasink L . Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial. JAMA. 2019; 322(17):1661-1671. PMC: 6865224. DOI: 10.1001/jama.2019.15468. View

19.

Aliberti S, Zanaboni A, Wiemken T, Nahas A, Uppatla S, Morlacchi L . Criteria for clinical stability in hospitalised patients with community-acquired pneumonia. Eur Respir J. 2012; 42(3):742-9. DOI: 10.1183/09031936.00100812. View

20.

Karaiskos I, Giamarellou H . Carbapenem-Sparing Strategies for ESBL Producers: When and How. Antibiotics (Basel). 2020; 9(2). PMC: 7167803. DOI: 10.3390/antibiotics9020061. View